Guardant Health (GH) Tops Q2 EPS by 33c; Offers Guidance

Guardant Health (NASDAQ: GH) reported Q2 EPS of ($0.42), $0.33 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $334.97 million versus the consensus estimate of $314.23 million.

GUIDANCE:

Guardant Health sees FY2026 revenue of $1.34-1.36 billion, versus the consensus of $1.31 billion.

For earnings history and earnings-related data on Guardant Health (GH) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Electra Therapeutics files for proposed IPO
• Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56